Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek
Provided By GlobeNewswire
Last update: Nov 5, 2024
MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas.
Read more at globenewswire.com0.5229
-0.01 (-2.12%)
Find more stocks in the Stock Screener
VERU Latest News and Analysis
20 days ago - ChartmillWhich stocks are experiencing notable movement on Tuesday?Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
20 days ago - ChartmillLet's uncover which stocks are experiencing notable gaps during today's session.There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
